TABLE III.

Change in dose to the superficial parotid lobes in patients with nasopharyngeal carcinoma at different T, N, and clinical stages, using superficial parotid lobe–sparing technology

Variable	Patients (n)	Superficial lobe	Dose in test plan (Gy)	Dose reduction (Gy)
T stage
T1	7	Left	27.4	4.8
		Right	28.5	4.6
T2	6	Left	29.7	1.6
		Right	28.8	1.5
T3	13	Left	29.2	3.9
		Right	30.4	3.2
T4	5	Left	30.3	8.5
		Right	30.6	8.2
N stage
N0	7	Left	29.2	3.8
		Right	31.2	3.6
N1	8	Left	30.4	2.4
		Right	29.5	2.3
N2	12	Left	28.6	5.7
		Right	29.5	5.6
N3	4	Left	27.5	5.4
		Right	28.3	3.1
Clinical stage
i	2	Left	26.6	3.8
		Right	30.0	3.6
ii	6	Left	30.7	2.4
		Right	29.6	2.3
iii	14	Left	28.7	5.7
		Right	29.7	5.6
iva–ivb	9	Left	29.0	5.4
		Right	29.6	3.2